The cell and gene therapy manufacturing sphere continues to mature rapidly, with a growing number of companies moving towards commercialising products. This report includes a European Heatmap which provides a high level overview of the latest developments in the European cell and gene therapy manufacturing space, in addition to an detailed industry update which provides information about therapy development throughout Europe.
As cell and gene therapy production continues to move towards commercialisation, it faces new challenges relating to the scalability of manufacturing processes. Both autologous and allogeneic therapies hold their own unique obstacles relating to production and treatment; and the promise of personalised medicines is not without hindrances related to both cost and availability.
We interviewed Andrew Finnerty, General Manager, CCMI Ireland at NUI Galway to discuss this topic in more detail and build a better understanding of how the rapid expansion of this market has brought about new challenges relating to manufacturing scalability , and what will this mean for the future of personalised cell and gene therapies.
Fast on its way to becoming a multibillion-dollar market, the global cell and gene therapy industry is booming. However, challenges mean that almost three decades after the first gene therapy trial, only three gene therapies have been approved in the EU and one in the United States. This article will look into the challenges around development and manufacturing that need to be addressed so that ambitious pharma and biotechs can continue to develop these innovative medicines.
The cell and gene therapy manufacturing sphere continues to mature rapidly, with a growing number of companies moving towards commercialising products. This infographic provides a high level overview of the latest developments in the European cell and gene therapy manufacturing space, looking at which therapies are moving into commercialisation in order to treat a wide range of conditions and diseases.
In response to the region’s strengthening presence with the therapeutic method, Pharma IQ presents this Cell and Gene Manufacturing hotspot map.